share_log

Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Benzinga ·  May 17, 2023 22:08

Canaccord Genuity analyst Edward Nash maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Hold and lowers the price target from $3 to $2.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment